 Melanie Gleason
Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| School Health Services | 10 | 2024 | 238 | 1.330 |
Why?
| | Asthma | 21 | 2024 | 2295 | 1.130 |
Why?
| | School Nursing | 4 | 2024 | 32 | 0.590 |
Why?
| | Health Personnel | 2 | 2017 | 710 | 0.410 |
Why?
| | Anti-Asthmatic Agents | 6 | 2017 | 395 | 0.310 |
Why?
| | Respiratory Sounds | 1 | 2022 | 125 | 0.180 |
Why?
| | Child | 20 | 2024 | 21935 | 0.160 |
Why?
| | Program Development | 2 | 2018 | 364 | 0.150 |
Why?
| | Schools | 4 | 2022 | 461 | 0.150 |
Why?
| | Population | 1 | 2018 | 35 | 0.150 |
Why?
| | Self Care | 2 | 2016 | 380 | 0.130 |
Why?
| | Competency-Based Education | 1 | 2016 | 73 | 0.120 |
Why?
| | Disease Management | 2 | 2018 | 628 | 0.120 |
Why?
| | Urban Population | 1 | 2018 | 479 | 0.120 |
Why?
| | Prednisone | 2 | 2015 | 240 | 0.110 |
Why?
| | Nurse's Role | 1 | 2016 | 161 | 0.110 |
Why?
| | Program Evaluation | 1 | 2018 | 898 | 0.110 |
Why?
| | Evidence-Based Practice | 1 | 2016 | 229 | 0.100 |
Why?
| | Colorado | 6 | 2024 | 4565 | 0.100 |
Why?
| | Virus Diseases | 1 | 2015 | 212 | 0.100 |
Why?
| | Adolescent | 13 | 2024 | 21513 | 0.100 |
Why?
| | Child, Preschool | 9 | 2022 | 11074 | 0.090 |
Why?
| | Healthcare Disparities | 1 | 2018 | 654 | 0.090 |
Why?
| | Communication | 1 | 2017 | 879 | 0.090 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1587 | 0.090 |
Why?
| | Spirometry | 3 | 2022 | 281 | 0.090 |
Why?
| | Nitric Oxide | 1 | 2015 | 915 | 0.080 |
Why?
| | Health Promotion | 1 | 2016 | 741 | 0.080 |
Why?
| | Humans | 23 | 2024 | 137585 | 0.080 |
Why?
| | Parents | 1 | 2017 | 1347 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 1 | 2012 | 558 | 0.080 |
Why?
| | Immunoglobulin E | 1 | 2010 | 342 | 0.070 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2008 | 89 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2012 | 565 | 0.070 |
Why?
| | Food Hypersensitivity | 1 | 2010 | 183 | 0.070 |
Why?
| | Aminopyridines | 1 | 2008 | 98 | 0.070 |
Why?
| | Benzamides | 1 | 2008 | 216 | 0.070 |
Why?
| | Health Services Accessibility | 2 | 2018 | 986 | 0.070 |
Why?
| | Dermatitis, Atopic | 1 | 2010 | 329 | 0.070 |
Why?
| | Acetates | 1 | 2006 | 99 | 0.060 |
Why?
| | Quinolines | 1 | 2006 | 178 | 0.060 |
Why?
| | Female | 15 | 2024 | 73304 | 0.060 |
Why?
| | Drug Labeling | 1 | 2003 | 39 | 0.050 |
Why?
| | Anti-Allergic Agents | 1 | 2003 | 46 | 0.050 |
Why?
| | Vulnerable Populations | 1 | 2024 | 163 | 0.050 |
Why?
| | Patient Dropouts | 1 | 2003 | 67 | 0.050 |
Why?
| | Male | 14 | 2018 | 67762 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2003 | 208 | 0.050 |
Why?
| | Methacholine Chloride | 1 | 2022 | 52 | 0.050 |
Why?
| | Bronchial Provocation Tests | 1 | 2022 | 51 | 0.050 |
Why?
| | Forced Expiratory Volume | 3 | 2015 | 531 | 0.050 |
Why?
| | Patient Compliance | 1 | 2003 | 581 | 0.040 |
Why?
| | Connecticut | 1 | 2018 | 27 | 0.040 |
Why?
| | Case Management | 1 | 2018 | 66 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2003 | 1050 | 0.040 |
Why?
| | Absenteeism | 1 | 2018 | 49 | 0.040 |
Why?
| | Cyclopropanes | 2 | 2008 | 90 | 0.030 |
Why?
| | Respiratory Function Tests | 2 | 2012 | 600 | 0.030 |
Why?
| | Community Health Services | 1 | 2018 | 227 | 0.030 |
Why?
| | Nursing Education Research | 1 | 2016 | 44 | 0.030 |
Why?
| | Organizational Case Studies | 1 | 2016 | 78 | 0.030 |
Why?
| | Airway Resistance | 2 | 2006 | 41 | 0.030 |
Why?
| | Plethysmography | 2 | 2006 | 106 | 0.030 |
Why?
| | Research Design | 1 | 2022 | 1139 | 0.030 |
Why?
| | Exhalation | 1 | 2015 | 39 | 0.030 |
Why?
| | Breath Tests | 1 | 2015 | 87 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2005 | 2691 | 0.030 |
Why?
| | Patient Education as Topic | 2 | 2014 | 766 | 0.030 |
Why?
| | Focus Groups | 1 | 2017 | 522 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 951 | 0.030 |
Why?
| | Drug Resistance | 2 | 2012 | 169 | 0.030 |
Why?
| | Family | 1 | 2018 | 671 | 0.030 |
Why?
| | Acute Disease | 1 | 2015 | 1007 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 1062 | 0.020 |
Why?
| | Dual Specificity Phosphatase 1 | 1 | 2012 | 26 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2015 | 496 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 268 | 0.020 |
Why?
| | Receptors, Glucocorticoid | 1 | 2012 | 155 | 0.020 |
Why?
| | Immunoassay | 1 | 2010 | 115 | 0.020 |
Why?
| | Double-Blind Method | 2 | 2006 | 1993 | 0.020 |
Why?
| | Dexamethasone | 1 | 2012 | 368 | 0.020 |
Why?
| | Food | 1 | 2010 | 164 | 0.020 |
Why?
| | Students | 1 | 2014 | 622 | 0.020 |
Why?
| | Clinical Competence | 1 | 2016 | 1118 | 0.020 |
Why?
| | Half-Life | 1 | 2008 | 164 | 0.020 |
Why?
| | Glucocorticoids | 1 | 1992 | 594 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2008 | 2057 | 0.020 |
Why?
| | Area Under Curve | 1 | 2008 | 314 | 0.020 |
Why?
| | Allergens | 1 | 2010 | 409 | 0.020 |
Why?
| | Insurance, Health | 1 | 2009 | 283 | 0.020 |
Why?
| | Lung Volume Measurements | 1 | 2006 | 46 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2008 | 597 | 0.020 |
Why?
| | Oscillometry | 1 | 2006 | 42 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2008 | 564 | 0.020 |
Why?
| | Sulfides | 1 | 2006 | 99 | 0.010 |
Why?
| | United States | 2 | 2018 | 14841 | 0.010 |
Why?
| | Tandem Mass Spectrometry | 1 | 2008 | 532 | 0.010 |
Why?
| | Electrocardiography | 1 | 2008 | 629 | 0.010 |
Why?
| | Airway Obstruction | 1 | 2006 | 162 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2475 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2012 | 4193 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5472 | 0.010 |
Why?
| | Nedocromil | 1 | 2003 | 32 | 0.010 |
Why?
| | Infant | 2 | 2010 | 9465 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2012 | 1996 | 0.010 |
Why?
| | Prognosis | 1 | 2012 | 4030 | 0.010 |
Why?
| | Budesonide | 1 | 2003 | 89 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 7604 | 0.010 |
Why?
| | Adult | 2 | 2018 | 37929 | 0.010 |
Why?
| | Social Class | 1 | 2003 | 282 | 0.010 |
Why?
| | Social Behavior | 1 | 2003 | 287 | 0.010 |
Why?
| | Hypersensitivity | 1 | 2003 | 257 | 0.010 |
Why?
| | Social Support | 1 | 2003 | 618 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2003 | 2844 | 0.010 |
Why?
| | Cognition | 1 | 2003 | 1153 | 0.010 |
Why?
| | Inflammation | 1 | 2005 | 2837 | 0.010 |
Why?
| | Young Adult | 1 | 2010 | 13209 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2010 | 15657 | 0.010 |
Why?
| | Theophylline | 1 | 1992 | 67 | 0.010 |
Why?
| | Albuterol | 1 | 1992 | 110 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1992 | 688 | 0.010 |
Why?
|
|
Gleason's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|